Authors/Disclosures
|
Timothy M. Miller, MD, PhD
(Washington University)
|
Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ionis Pharmaceuticals. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Disarm Therapeutics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen IDEC. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care. |
|
Richard A. Smith, MD
(Center for Neurologic Study)
|
Dr. Smith has received personal compensation for serving as an employee of Center for Neurologic Study. Dr. Smith has received intellectual property interests from a discovery or technology relating to health care. Dr. Smith has received intellectual property interests from a discovery or technology relating to health care. Dr. Smith has received publishing royalties from a publication relating to health care. Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving as a Inventor with Ionis Pharmaceutical. |
|
Alan Pestronk, MD, FAAN
(Washington University in Saint Louis - Neurology)
|
The institution of Dr. Pestronk has received research support from Jain. The institution of Dr. Pestronk has received research support from Fulcrum. The institution of Dr. Pestronk has received research support from Argenyx. The institution of Dr. Pestronk has received research support from NeuroNext. |
|
William S. David, MD, PhD, FAAN
(EMG /Neuromuscular Unit)
|
Dr. David has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dysimmune Disorders foundation. Dr. David has received publishing royalties from a publication relating to health care. |
|
Jeffrey D. Rothstein, MD, PhD
(Johns Hopkins University)
|
Dr. Rothstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Expansion Therapeutics. Dr. Rothstein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal Clinical Investigation. The institution of Dr. Rothstein has received research support from ALSA. The institution of Dr. Rothstein has received research support from MDA. The institution of Dr. Rothstein has received research support from F Prime. The institution of Dr. Rothstein has received research support from Target ALS. The institution of Dr. Rothstein has received research support from Chan Zuckerberg Initiative. The institution of Dr. Rothstein has received research support from Dept of Defense. Dr. Rothstein has received intellectual property interests from a discovery or technology relating to health care. |
|
Ericka P. Greene, MD, FAAN
(Methodist Hospital)
|
Dr. Greene has received personal compensation for serving as an employee of Argenx. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion, Inc. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylx. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Greene has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis . Dr. Greene has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ABPN. |
|
Patricia Andres, PT
(Massachusetts General Hospital)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Kathie M. Bishop, PhD
|
Dr. Bishop has received personal compensation for serving as an employee of Acadia Pharmaceuticals, Inc. . Dr. Bishop has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for DTx Pharma. Dr. Bishop has stock in Acadia Pharmaceuticals, Inc.. |
|
Eric A. Macklin, PhD
(Massachusetts General Hospital)
|
The institution of Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AI Therapeutics. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chase Therapeutics. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial Biotech. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoparkinson Healthcare LLC. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Macklin has received research support from Biohaven. The institution of Dr. Macklin has received research support from Clene Nanomedicine. The institution of Dr. Macklin has received research support from Mitsubishi Tanabe Pharmaceuticals America. The institution of Dr. Macklin has received research support from Prilenia. The institution of Dr. Macklin has received research support from UCB Ra Pharma. The institution of Dr. Macklin has received research support from Revalesio. The institution of Dr. Macklin has received research support from Seelos. The institution of Dr. Macklin has received research support from Calico. The institution of Dr. Macklin has received research support from Denali. The institution of Dr. Macklin has received research support from NeuroDex. The institution of Dr. Macklin has received research support from Alector. The institution of Dr. Macklin has received research support from ITB-Med. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Jared Gollob, MD
(Alnylam Pharmaceuticals)
|
No disclosure on file |